Granted Patent B2

US 12,178,875 · App. 18/425,761 · Granted Dec 31, 2024

Inventors: Daniel Kenneth Bonner (Sharon, MA); Ketki Karanam (Newton, MA); James Tendai Mutamba (Newton, MA); Rishab R. Shyam (Arlington, MA); Jamie Simpson (Chestnut Hill, MA); Sifei Han (Bundoora, AU); Luojuan Hu (Bundoora, AU); Christopher John Hamilton Porter (South Melbourne, AU); Tim Quach (Boston, MA); Natalie Trevaskis (Newington, AU)

Assignees: Seaport Therapeutics, Inc.; Monash University

A61K47/543A61K45/06

Abstract

Claims (16)

1. A compound of Formula X-b:

wherein R 1 and R 2 are each independently a fatty acid having a C 4 -C 18 chain;

one instance of R 4 is hydrogen and one instance of R 4 is methyl;

-M- is

and

A is cannabidiol.

2. A pharmaceutical composition comprising the compound according to claim 1 , and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

3. The pharmaceutical composition according to claim 2 , wherein the pharmaceutical composition is formulated for oral administration.

4. An oral dosage form comprising the compound according to claim 1 .

5. The oral dosage form of claim 4 , further comprising a lipid-based vehicle.

6. The oral dosage form of claim 4 , wherein the oral dosage form comprises a self-emulsifying drug delivery system (SEDDS).

7. The oral dosage form of claim 4 , wherein the oral dosage form is a capsule.

8. The compound according to claim 1 , wherein R 1 and R 2 are each independently a fatty acid having a C 6 -C 16 chain.

9. The compound according to claim 8 , wherein each fatty acid is a saturated fatty acid.

10. The compound according to claim 9 , wherein each saturated fatty acid is a straight-chain fatty acid.

11. The compound according to claim 1 , wherein the compound is:

Assignments (9)

Continuity (8)